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11 Abstract Long-term survival of patients with systemic lupus
12 erythematosus (SLE) improved worldwide; thus, prevention
13 of cumulative organ damage became a major goal in disease
14 management. The aim of our study was to investigate the
15 chronic organ damages and their influence on disease out-
16 come in SLE. We evaluated clinical conditions, laboratory
17 findings and medications of 357 consecutive SLE patients
18 and assessed their impact on Systemic Lupus Collaborating
19 Clinics (SLICC)/American College of Rheumatology (ACR)
20 Damage Index (SDI) and disease outcome.We detected one or
21 more SDI scores in 77.87% of patients. Patients with disease
22 duration of more than 10 years and subjects diagnosed at age
23 above 40 had significantly higher SDI values. The most fre-
24 quent damages were valvulopathies, cognitive dysfunction,
25 angina pectoris and venous thrombosis. Higher cumulative
26 glucocorticoid dose increased SDI, while chloroquin treat-
27 ment was favourable for patients. Male gender, elevated SDI
28 scores and higher cumulative doses of glucocorticoids in-
29 creased mortality risk. Our data confirmed that disease dura-
30 tion, age at diagnosis and chronic high-dose glucocorticoid
31 therapy have significant effects on the development of chronic
32 organ damage. Higher SDI score is characterized with worse
33 survival ratios. The most common chronic organ damages
34 affected the cardiovascular or neuropsychiatric system. As
35 long-term survival in SLE improves, it becomes increasingly
36 important to identify the determinants of chronic organ dam-
37 age. Most of the chronic organ damage occurs in the cardio-
38 vascular and the neuropsychiatric systems; thus, regular
39follow-up, screening and adequate therapy are essential for
40the best clinical outcome.
41Keywords Chronic organ damage . Disease outcome .
42SLICC/ACRDamage Index . Systemic lupus erythematosus
43Introduction
44Systemic lupus erythematosus (SLE) is a chronic autoimmune
45disease that can affect almost any organs and tissues of the
46body, leading to a wide spectrum of clinical manifestations.
47For a long time, lupus was considered to be a disease with a
48poor prognosis, but in recent years, the long-term survival in
49SLE has improved significantly. While during the 1960s, the 5-
50year survival rate was 60%, by the 2000s, it has increased up to
5190% in most countries and centres [1, 2], although ethnic and
52geographic variations remained significant [3, 4]. However, the
53increased longevity of patients with SLE leads to the accumu-
54lation of chronic organ damage over time in patients, which
55became one of the most important factors that contribute to
56mortality in SLE [5]. Disease activity and certain comorbidities
57are the main factors; however, several other factors are known
58to influence the development of chronic organ damage.
59Importantly, immunomodulatory treatments can be also associ-
60ated with adverse events, organ damages and mortality. La
61Gonzales et al. identified menopause as well as gender, age
62and ethnicity as further significant influencing factors; more-
63over, they reported that certain psychosocial factors can also
64promote chronic damage [6]. Therefore, it is important to ex-
65amine and understand the factors and mechanisms that influ-
66ence disease prognosis and patients’ quality of life.
67The Systemic Lupus Collaborating Clinics (SLICC) and the
68American College of Rheumatology (ACR) proposed the inter-
69nationally validated damage scoring system, namely, SLICC/
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70 ACR Damage Index (SDI) for the evaluation of chronic organ
71 damage. SDI can be used to measure the degree of damage and
72 to check its change over time [7]. Previous studies revealed
73 significant associations between damage; disease activity; and
74 certain demographic, clinical and laboratory features [8, 9].
75 Due to lack of data from East-Central Europe, the aims of
76 our work were to survey SDI values in a large cohort of
77 Hungarian SLE patients, to compare our results with interna-
78 tional data and to identify additional influencing factors.
79 Material and methods
80 Patients
81 In our present cross-sectional study, we evaluated 357
82 Hungarian patients with SLE who were diagnosed between
83 1 January 1971 and 31 December 2012 and also treated at the
84 Division of Clinical Immunology in the Medical Center of
85 University of Debrecen. All patients were followed up on a
86 routine basis, and their records contained detailed information
87 on symptoms, clinical conditions, laboratory and other find-
88 ings of each visit. The diagnosis of SLE was established based
89 on the ARA preliminary classification criteria or ACR classi-
90 fication criteria revised in 1982 or in 1997, according to the
91 date of first visit [10–12]. Patients diagnosed with SLE before
92 1997 were revised according to the revised 1997 ACR criteria
93 for SLE classification. Sapporo and Sydney criteria were used
94 to establish the diagnosis of anti-phospholipid syndrome [13,
95 14]. All experiments carried out in the study were in compli-
96 ance with the Declaration of Helsinki.
97 Clinical evaluations
98 All patients were followed up on a routine basis, and their
99 records contained detailed information on symptoms, clinical
100 conditions and laboratory and other findings of each visit. The
101 following demographic and clinical data were analyzed: gen-
102 der, age, age at diagnosis, duration of disease, clinical symp-
103 toms and organ manifestations of SLE, comorbidities, labora-
104 tory parameters, immunoserological abnormalities and thera-
105 py used during the disease course. DQ1 isease activity was mea-
106 sured using Systemic Lupus Erythematosus Disease Activity
107 Index (SLEDAI) [15, 16]; flare was defined as an increase in
108 SLEDAI score with at least 3 points. The assessment of chron-
109 ic organ damage was performed using SDI [7].
110 Laboratory measurements
111 Immunoserological tests were performed at the Regional
112 Immunology Laboratory of the Division of Clinical
113 Immunology and included the measurement of anti-
114 nuclear antibody (ANA), rheumatoid factor (RF),
115antibodies against extractable nuclear antigen (ENA), an-
116ti-dsDNA, anti-Sm, anti-RNP, anti-SS-A, anti-SS-B, anti-
117phospholipid antibodies, serum immunoglobulins,
118haemolysis test and complement levels. Hep-2 cell-based
119indirect immunofluorescence assay was performed as a
120screening test for anti-ENA antibodies, and further iden-
121tification was carried out by enzyme-linked immunosor-
122bent assay (ELISA) with AUTOSTAT II kits (Hycor
123Biomedical, Indianapolis, IN, USA), according to the
124manufacturer’s instructions. Immunoglobulin levels and
125complement activity were determined with turbidimetry
126and nephelometry techniques and haemolysis test in sheep
127red blood cell suspension, respectively. General laboratory
128parameters (blood count, kidney and liver function,
129haemostasis parameters, lupus anti-coagulant, urinalysis)
130were assessed at the Clinical Biochemistry and Molecular
131Pathology Institute of University of Debrecen.
132Therapy
133We registered the use of medications, including glucocorti-
134coids, immunosuppressive agents, hydroxychloroquine and
135biologics. Additionally, we also calculated the cumulative
136dosage of glucocorticoids and analyzed the relationship be-
137tween SDI and the different treatment modalities.
138Statistical analyses
139The IBM SPSS ver. 22.0 (SPSS Inc., Chicago, IL, UDA)
140was used for statistical analysis. In cases of continuous
141variable, we determined mean and standard deviation
142(SD) values and used independent samples t test or
143Mann-Whitney test for statistical evaluation. When the
144strength of the linear relationship between two variables
145was evaluated, Pearson’s correlation coefficient was used,
146while in cases of non-normal distribution, Spearman’s cor-
147relation coefficient was applied. Chi-square test and
148Fisher’s exact test were used to discriminate between pa-
149tient groups. Data on disease outcome are given in mean
150values with 95% confidence intervals (CIs). We used the
151Cox regression model to predict chronic organ develop-
152ment in the disease. Survival time and rate were assessed
153using the Kaplan-Meier estimator. Chi-square test and
154Fisher’s exact test were used to discriminate between pa-
155tient groups, and we used the Cox regression model to
156predict poor outcome of the disease. Differences were con-
157sidered statistically significant at p < 0.05.
158Results
159Table 1 summarizes the demographic data and clinical and lab-
160oratory features of the 357 SLE patients. The mean follow-up
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161 period was 19.14 ± 9.15 years with a range 1 to 44 years. The
162 mean age of patients at the time of their last follow-up visits was
163 51.57 ± 13.48 years with a range 21 to 86 years, while their
164 mean age at disease onset was 32.11 ± 11.49 years (range 7–
165 67 years). There were 33 male (9.24%) and 324 female
166 (90.76%) patients; male to female ratio was 9.8:1.
167Chronic organ damage
168Based on our observations, men had higher mean SDI value
169(SDI: 2.03 ± 1.55) compared to women (SDI 1.88 ± 1.73), but
170the difference was not significant.
171Out of 357 patients, 278 patients (77.87%) were found to
172have developed at least one chronic organ damage. Damage
173scores 1 and 2 were the most frequent [N = 104 (29.13%) and
174N = 62 (17.37%), respectively], followed by scores 3 and 4
175[N = 56 (15.69%) and N = 25 (7%), respectively] and scores 5
176and 6–8 [N = 15 (4.2%) and N = 16 (4.48%), respectively].
177The cardiovascular organ system was the mostly affected in
178patients during the disease course (N = 108, 30.25%). Ninety-
179one patients (25.49%) were found to have developed neuro-
180psychiatric, 65 patients (18.21%) musculoskeletal and 57 pa-
181tients (15.97%) peripheral vascular, and both ocular and renal
182damage affected 56 patients (15.68%). Fifty patients (14.01%)
183were found to have dermatological, 35 patients (9.8%) pulmo-
184nary and 3 patients (0.84%) gastrointestinal organ system
185damage (Table 1). The ten most frequent types of chronic
186organ damage are listed in Fig. 1.
187Based on our results, the number of chronic damages was
188significantly higher in patients with disease duration of more
189than 10 years (mean SDI value of patients with disease duration
190of 6–10 years, 1.15 ± 1.68 vs. mean SDI value determined in
191patients with disease duration of 11–15 years, 2.02 ± 1.81, re-
192spectively, p = 0.014). Patients with a disease duration of more
193than 25 years had even higher SDI values (mean SDI value of
194patients with disease duration of 21–25 years, 2.21 ± 1.84 vs.
195mean SDI value determined in patients with disease duration of
196more than 25 years, 2.83 ± 2.14, respectively, p = 0.018) (Fig. 2).
197We examined the relationship between the SDI value and
198disease activity, as well. Of patients without chronic damage,
19925.32% developed a disease flare during the last 10 years of
200the study. Of patients with a score of 1–3, 28.63% showed
t1:1 Table 1 The main demographic, clinical and serological features of
SLE patients (n = 357)
t1:2 Demographic features
t1:3 Male/female 33/324
t1:4 Age (years) mean ± SD (range) 51.57 ± 13.48 (21–86)
t1:5 Age at disease onset (years) mean ± SD (range) 32.11 ± 11.49 (7–67)
t1:6 Disease duration (years) mean ± SD (range) 19.14 ± 9.15 (1–44)
t1:7 Clinical damages, N (%)
t1:8 Cardiovascular damage 108 (30.25)
t1:9 Neuropsychiatric damage 91 (25.49)
t1:10 Musculoskeletal damage 65 (18.21)
t1:11 Peripheral vascular damage 57 (15.97)
t1:12 Ocular damage 56 (15.68)
t1:13 Renal damage 56 (15.68)
t1:14 Skin damage 50 (14.01)
t1:15 Pulmonary damage 35 (9.8)
t1:16 Gastrointestinal damage 3 (0.84)
t1:17 Serological abnormalities, N (%) last time of the follow-up
t1:18 ANA 355 (99.44)
t1:19 Anti-dsDNA 195 (54.62)
t1:20 Anti-Sm 86 (24.09)
t1:21 Anti-SSA 99 (27.73)
t1:22 Anti-SSB 59 (16.53)
t1:23 Anti-cardiolipin IgG/IgM 86 (24.09)
t1:24 Anti-beta2 GPI IgG/IgM 75 (21.01)
t1:25 Lupus anti-coagulant 24 (6.72)
t1:26 Low C3/C4 153 (42.86)
t1:27 Medications, N (%)
t1:28 Glucocorticoids 310 (86.83)
t1:29 Cumulative dosage of glucocorticoids (g) mean ± SD 32.878 ± 25.506
t1:30 Chloroquine 158 (44.26)
t1:31 Azathioprine 171 (47.9)
t1:32 Cyclophosphamide 103 (28.85)
t1:33 Methotrexate 40 (11.2)
t1:34 Biologics 36 (10.08)
t1:35 Cyclosporine A 21 (5.88)
t1:36 Leflunomide 16 (4.48)
t1:37 Mycophenolate mofetil 12 (3.36)
Fig. 1 Percentages of the ten
most frequent specific chronic
organ damages in SLE patients
(n = 357)
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201 active disease. Of patients with an SDI value of at least 4,
202 32.29% demonstrated disease flare. The increase in SDI
203 values was mirrored by an increase in the number of patients
204 with disease flare, but the difference was not significant.
205 The patients’mean age at diagnosis had an influence on the
206 SDI value. The SDI value of SLE patients who were diag-
207 nosed above the age of 40 years (N = 102) was significantly
208 higher than the mean SDI value of patients diagnosed under
209 40 years (N = 255) (2.28 ± 1.92 vs. 1.74 ± 1.6, respectively,
210 p = 0.007).
211 We also investigated the relationship between SDI and the
212 different treatment modalities. Regarding long-term glucocor-
213 ticoid therapy, patients with a higher SDI score (6–8) had a
214 significantly higher (p < 0.001) cumulative glucocorticoid
215 dose than patients with lower SDI scores (1–2). Patients who
216 received higher-dose glucocorticoid therapy had higher mean
217 SDI scores (Fig. 3). Furthermore, significantly higher average
218cumulative glucocorticoid dose was administered to SLE pa-
219tients with cataracts (p < 0.001) or osteoporosis (p = 0.041).
220Cumulative doses were also higher in patients with cerebro-
221vascular events, lower extremity claudication, myopathy and
222avascular necrosis of the femoral head, but the difference was
223not statistically significant. We also revealed a strong positive
224correlation between SDI values and cumulative glucocorticoid
225doses in the whole cohort of SLE patients (R = 0.307, respec-
226tively, p < 0.001). Moreover, adjusted odds ratios (ORs) by
227multiple logistic regression analysis showed that cumulative
228doses were significantly and independently related to SDI
229(OR 0.05, respectively, p = 0.027).
230Interestingly, the mean SDI value of patients treated with
231chloroquine (N = 158) was significantly lower than that of
232lupus patients not receiving chloroquine (1.64 ± 4.54 vs.
2332.1 ± 1.82, respectively, p = 0.024). In the cases of cyclophos-
234phamide, azathioprine, methotrexate, cyclosporine A and
Fig. 2 Association between the
disease duration and SDI. Patients
with disease duration of more
than 10 years had higher SDI
values (*p = 0.014). Patients with
disease duration of more than
25 years had even higher SDI
values (**p = 0.018)
Fig. 3 The effect of long-term
glucocorticoid therapy on SDI
values. Patients with the highest
SDI values (6–8) had a
significantly higher average
cumulative glucocorticoid dose
compared to patients with lower
SDI values (0–5) (*p < 0.001)
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235 other investigated therapies, there was no significant differ-
236 ence between the mean SDI values of treated and non-
237 treated patients. We did not find any associations between
238 serological parameters and SDI values.
239 Disease outcome
240 During thewhole follow-up period, 42 (32women and 10men)
241 of our patients died. Mortality of the whole patient population
242 was 11.76%; of note, mortality values differed significantly
243 between male and female patients (30.3 vs. 9.88%, respective-
244 ly, p = 0.002). As to the distribution by age groups, we lost 20
245 (17 female and 3 male), 18 (13 female and 5 male) and 4 (2
246 female and 2 male) patients, from the >60 years, the 40–
247 59 years and the <40 age groups, respectively.When evaluating
248 the causes of death, infections (N = 15) and cardiovascular
249 events, such as myocardial infarction (N = 11) and stroke
250 (N = 3), were the leading causes, being followed by heart failure
251 (N = 3) and tumours including lung (N = 3), breast (N = 2), liver
252 (N = 1) and brain cancers (N = 1), as well as malignant mela-
253 noma (N = 1) and non-Hodgkin’s lymphoma (N = 2).
254 The overall 5-year survival rate was 99%, the 10-year sur-
255 vival rate was 98%, and the 15-year survival rate was 95%.
256 The mean survival was 37.21 years [95% confidence interval
257 (CI), 35.33–39.1]. Male patients and patients with 5 or more
258 SDI score could be characterized with significantly worse sur-
259 vival ratios. The mean survival of male patients was signifi-
260 cantly worse, compared to the values of female patients
261 [28.78 years (95% CI, 24.82–32.74) vs. 38.19 years (36.24–
262 40.15), respectively, p < 0.001]. Moreover, patients with 5 or
263 more SDI score had significantly shortened mean survival
264 time than patients with 4 or less SDI score [24.05 years
265 (95%CI, 20.75–27.35) vs. 43.79 years (42.66–44.93), respec-
266 tively, p < 0.0001] (Fig. 4a, b).
267Cox regression analyses revealed three independent prog-
268nostic factors: male gender, >4 SDI score and higher cumula-
269tive glucocorticoid doses have significant negative effect on
270disease outcome [male gender: hazard ratio (HR), 2.785 (95%
271CI, 1.35–5.719), respectively, p = 0.005; >4 SDI score: HR,
27255.12 (95% CI, 19.15–158.63), respectively, p < 0.001; cu-
273mulative glucocorticoid doses: HR, 1.02 (95% CI, 1.006–
2741.035), respectively, p = 0.005].
275Discussion
276In SLE, chronic organ damage has become an increasingly im-
277portant factor beyond disease activity. Many factors such as
278geographic and ethnic determinants can affect the severity and
279course of the disease as well as the development of organ dam-
280age. In spite of the wealth in international data, our information
281on chronic organ damage and understanding of its determinants
282in SLE patients in East-Central Europe is incomplete, and the
283results measured by various centres diverge on several points.
284Our results show that the patient’s gender does not influ-
285ence the development of chronic organ damages. Yee et al.
286and Estevez del Toro et al. obtained similar results in British
287and Cuban patients, respectively [17, 18]. In contrast,
288Andrade et al. found that male patients developed chronic
289organ damage faster and in larger numbers [19]. The incidence
290of the most common damages can vary. Among our patients,
291the most frequent damages were found in the cardiovascular
292and neuropsychiatric organ systems. The largest numbers of
293chronic organ damage were found in the renal and musculo-
294skeletal systems [20], the musculoskeletal and dermal systems
295[18] and the neuropsychiatric system [21].
296We made the assumption that among patients with longer
297disease duration, the number of chronic organ damages may
Fig. 4 Kaplan-Meier survival plots for patients subgroups. aMale and female patients. b Patients with SDI value >4 and <5
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298 be increased. An additional complicating factor was that these
299 patients might have been treated with several types of immu-
300 nosuppressive therapies. Duration of disease has been desig-
301 nated as a factor in chronic damage by several centres [21].
302 There is disagreement in the results as to whether SDI value
303 shows a linear increase with disease duration. A gradual in-
304 crease was found by Cassano [22] in the Argentinian SLE
305 population, and a similar linear increase was measured by
306 Gladman et al. [23]. In agreement with our results, a gradual
307 increase followed by a “plateau phase” after certain duration
308 of disease was described by Becker-Merock and Nossent [24].
309 Interestingly, we found that the prevalence of chronic damage
310 was 77.9% in our Hungarian SLE cohort, which is higher
311 compared with other European cohort [5, 17]. This difference
312 can be explained by our results, since the follow-up of our
313 patients was longer, compared with the other cohorts, and
314 based on our observations, a significant increase in SDI values
315 develops typically 10 years after diagnosis.
316 During the course of SLE, chronic damage may develop with
317 a higher frequency among patients with increased disease activ-
318 ity. As described earlier by Lopez et al., disease activity mea-
319 sured by BILAG predicted later damages [25]. In their 5-year
320 prospective study, Stoll et al. found that disease activity defined
321 the development of chronic damages [26]. Although we did not
322 detect a significant difference in the course of the present study,
323 the number of patients showing active disease during the prior
324 10 years was higher among SLE patientswith higher SDI values.
325 Similar to our results, Maddison et al. described the
326 role of mean age at the time of diagnosis. Higher SDI
327 values were found among patients who were diagnosed
328 after the age of 40 years than those diagnosed under 40
329 [27]. In contrast, Morgan et al. found that young and
330 adolescent SLE patients sustain more damage over time
331 [28]. In his study of Chinese lupus patients, Feng com-
332 pared damages in patients with SLE diagnosed in child-
333 hood (under 18 years of age), youth (between 18 and
334 45 years of age) and old age (above 45 years of age);
335 no difference was found in the damage indexes [29].
336 Various aspects of the effects of glucocorticoids on chronic
337 organ damage were evaluated. Some publications examined
338 cumulative doses of glucocorticoids [30], while others studied
339 the average daily doses [20] or the potential effect of paren-
340 teral glucocorticoid therapy [31]. Mae Thaner et al. found that
341 the risk of irreversible damage increased with an increase of
342 the glucocorticoid dose. However, there was no significant
343 difference in the development of damage with administration
344 of low-dose (<180 mg/month) prednisolone [30]. Gladmann
345 et al. found that the amount of glucocorticoid administered
346 had an unequivocal effect on the development of cataracts
347 and a likely effect on cardiovascular events [23]. We also
348 found a strong association with high-dose glucocorticoid ther-
349 apy cataract and osteoporosis. Cumulative glucocorticoid
350 dose influenced also the cerebrovascular events, myopathy,
351lower extremity claudication and avascular necrosis of the
352femoral head, but the difference was not significant.
353Regarding immunosuppressive agents, we described the
354beneficial effect of chloroquine. Data from the Lumina cohort
355found that the SDI values of patients given initial chloroquine
356therapy were lower [32]. According to Akhavan et al., in the
357case of patients treated with chloroquine, less damage could
358be expected during the 3 years after diagnosis [33].
359Several other groups described that SLE patients treated
360with cyclophosphamide had higher mean SDI values [20,
36134]. However, we did not detect any direct correlation be-
362tween this and other immunosuppressive agents and the fre-
363quency of chronic organ damage among our patients. In con-
364trast, Mok and Akhavan described a significant correlation
365between azathioprine and chronic damage in Chinese and
366Canadian patients with SLE [33, 35]. A recent study demon-
367strated the possible role of anti-phospholipid antibodies in the
368development of organ damage [36]. We did not reveal any
369associations between serological features and SDI; however,
370the more careful assessment of anti-phospholipid antibody-
371positive patients is undoubtedly necessary.
372Significant gender differences were found in survival ratios;
373moreover, elevated SDI scores and higher cumulative doses of
374glucocorticoids increased mortality risk. This is in accordance
375with the fact that mortality ratios can improve and toxic adverse
376effects of glucocorticoids can be decreased by the usage of
377newer drugs with reduced glucocorticoid doses [37].
378Our results demonstrate that as long-term survival in SLE
379improves, it becomes increasingly important to survey the re-
380sults and to identify the determinants of chronic organ damage.
381Our data confirmed that disease duration, age at diagnosis and
382chronic high-dose glucocorticoid therapy have significant ef-
383fects on the development of chronic organ damage in the
384Hungarian patients with SLE. Our data are representative of
385East-Central European SLE population as well. Additionally,
386we confirmed the protective effect of chloroquine. Most of the
387chronic organ damage occurs in the cardiovascular and the
388neuropsychiatric systems; thus, regular follow-up, screening
389and adequate therapy are essential for the best clinical outcome.
390Compliance with ethical standards All experiments carried out in the
391study were in compliance with the Declaration of Helsinki.
392Disclosures None.
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